Sophie-Caroline Sacleux
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sophie-Caroline Sacleux has a total of 129 co-authors. Here are the top co-authors by number of shared publications:
- Faouzi Saliba
University Paris-Saclay, INSERM Unit 1193, France; AP-HP Hôpital Paul Brousse, Hepato-Biliary Centre, 94800 Villejuif, France
3 shared publications - Alexandre Louvet
Service des maladies de l'appareil digestif, University Hospital of Lille, Lille, France; Unite INSERM INFINITE, Lille, France
2 shared publications Faouzi Saliba
Liver Intensive Care Unit, AP-HP Hôpital Paul-Brousse, Centre Hépato-Biliaire, Villejuif, France
2 shared publications- Florent Artru
Liver Department, Rennes University Hospital and Rennes University, NuMeCan Institute, UMR INSERM 1317, Rennes Liver Failure Group, Rennes, France
2 shared publications - Georges-Philippe Pageaux
Hepato-gastroenterology Department, CHU Saint Eloi, Montpellier University
2 shared publications - José Ursic-Bedoya
Service d’hépatologie, hôpital Saint-Eloi, CHU de Montpellier, Université de Montpellier, Montpellier, France
2 shared publications
Latest Publications
- 7 July 2024
- Published by Elsevier in Journal of Hepatology
- Vol. 82 (1) , 62-71
Long-term outcome following liver transplantation of patients with ACLF grade 3
- 7 July 2024
- Published by Elsevier in Journal of Hepatology
- Vol. 82 (1) , 62-71
Long-term outcome following liver transplantation of patients with ACLF grade 3
- 12 June 2023
- Published by Elsevier in Journal of Hepatology
- Vol. 79 (3) , 717-727
The novel SALT-M score predicts 1-year post-transplant mortality in patients with severe acute-on-chronic liver failure
- 12 June 2023
- Published by Elsevier in Journal of Hepatology
- Vol. 79 (3) , 717-727
The novel SALT-M score predicts 1-year post-transplant mortality in patients with severe acute-on-chronic liver failure
- Open Access
- 31 May 2023
- Published by Elsevier in Journal of Hepatology
- Vol. 79 (1) , 79-92
Randomized, controlled clinical trial of the DIALIVE liver dialysis device versus standard of care in patients with acute-on- chronic liver failure
- 31 May 2023
- Published by Elsevier in Journal of Hepatology
- Vol. 79 (1) , 79-92
Open AccessRandomized, controlled clinical trial of the DIALIVE liver dialysis device versus standard of care in patients with acute-on- chronic liver failure
- Open Access
How to Optimize the Results of Liver Transplantation for Acute-on-Chronic Liver Failure
Cirrhotic patients who developed a decompensation episode requiring an admission to an intensive care unit are not equal in term of prognosis. This led to the definition of a syndrome, acute-on-chronic liver failure (ACLF), marked by the severity of systemic inflammation, the development of organ failures and a high short-term mortality. The most common underlying liver etiology is related to acute alcohol hepatitis in western countries and to HBV or HCV cirrhosis in eastern countries. Twenty-eight and 90-days high mortality rates are well linked to the number of organ failure and defined, merely ten years ago, by a modified SOFA score. ACLF is a dynamic syndrome and grading can vary from hospital admission. ACLF grading between day 3–7 of admission is more accurate for determining outcome. ACLF-3 patients with ≥3 organ failures remain very challenging with >75% mortality rate. Despite recent advances in the medical management of critically ill cirrhotic patients, the prognosis of these patients remains poor. Currently, the main effective treatment is an urgent liver transplantation (LT) which is performed in a very selected patients eligible to transplant given the limited availability of organ donors and the low post-transplant survival rates reported in earlier studies. Recently, large retrospective multicenter studies and registries showed an improved 1-year post-transplant survival rate >83% in several transplant centers. Nevertheless, only few proportions of the ACLF-2 and ACLF-3 patients are transplanted representing 0–10% of most liver transplant programs. A careful selection of these patients (excluding major comorbidities i.e., older age, addictology criteria, severe malnutrition…) and optimal timing for transplant (infection control, hemodynamic stability, low oxygen and vasopressor requirements) are associated with excellent post-transplant survival rate.
Open AccessHow to Optimize the Results of Liver Transplantation for Acute-on-Chronic Liver Failure
Cirrhotic patients who developed a decompensation episode requiring an admission to an intensive care unit are not equal in term of prognosis. This led to the definition of a syndrome, acute-on-chronic liver failure (ACLF), marked by the severity of systemic inflammation, the development of organ failures and a high short-term mortality. The most common underlying liver etiology is related to acute alcohol hepatitis in western countries and to HBV or HCV cirrhosis in eastern countries. Twenty-eight and 90-days high mortality rates are well linked to the number of organ failure and defined, merely ten years ago, by a modified SOFA score. ACLF is a dynamic syndrome and grading can vary from hospital admission. ACLF grading between day 3–7 of admission is more accurate for determining outcome. ACLF-3 patients with ≥3 organ failures remain very challenging with >75% mortality rate. Despite recent advances in the medical management of critically ill cirrhotic patients, the prognosis of these patients remains poor. Currently, the main effective treatment is an urgent liver transplantation (LT) which is performed in a very selected patients eligible to transplant given the limited availability of organ donors and the low post-transplant survival rates reported in earlier studies. Recently, large retrospective multicenter studies and registries showed an improved 1-year post-transplant survival rate >83% in several transplant centers. Nevertheless, only few proportions of the ACLF-2 and ACLF-3 patients are transplanted representing 0–10% of most liver transplant programs. A careful selection of these patients (excluding major comorbidities i.e., older age, addictology criteria, severe malnutrition…) and optimal timing for transplant (infection control, hemodynamic stability, low oxygen and vasopressor requirements) are associated with excellent post-transplant survival rate.
- 28 February 2023
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 29 (7) , 785-787
Evaluation of the transplantation of ACLF grade 3 model (TAM) in the multicenter French experience
An abstract is unavailable. This article is available as a PDF only.
- 28 February 2023
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 29 (7) , 785-787
Evaluation of the transplantation of ACLF grade 3 model (TAM) in the multicenter French experience
An abstract is unavailable. This article is available as a PDF only.
- Open Access
- 30 January 2021
- Published by MDPI AG in Microorganisms
- Vol. 9 (2) , 282
Susceptibility Testing Is Key for the Success of Cefiderocol Treatment: A Retrospective Cohort Study
Cefiderocol is a novel siderophore cephalosporin, which has proven in vitro activity against carbapenem-resistant (CR) Gram-negative pathogens and stability towards all carbapenemases. The aim of this study was to describe the first cases of prescriptions and the efficacy of cefiderocol for compassionate use in the 2 months following its access in France. We performed a national retrospective study of all patients who received at least one dose of cefiderocol from 2 November 2018 to 5 November 2019. We collected clinical characteristics and outcome through a standard questionnaire. Bacterial isolates from 12 patients were centralized and analyzed in the French National Reference Center for Antimicrobial Resistance, and sequenced using Illumina technology. Finally, 13 patients from 7 French university hospitals were included in the study. The main type of infection treated by cefiderocol was respiratory tract infections (RTI, n = 10). The targeted bacteria were Pseudomonas aeruginosa (n = 12), including carbapenemase-producing P. aeruginosa (n = 9), Acinetobacter baumannii (n = 2), Klebsiella pneumoniae (n = 1), and Enterobacter hormaechei (n = 1). Overall, of the 12 patients whose samples were analyzed, 5 P. aeruginosa strains were not susceptible to cefiderocol (4 categorized as resistant and 1 as intermediate) according to Clinical and Laboratory Standards Institute (CLSI) breakpoints. If considering susceptible strains, the cure rate was 6/7, while being 0/5 among not-susceptible strains. This study underlines the necessity to test strains in adequate conditions.
- 30 January 2021
- Published by MDPI AG in Microorganisms
- Vol. 9 (2) , 282
Open AccessSusceptibility Testing Is Key for the Success of Cefiderocol Treatment: A Retrospective Cohort Study
Cefiderocol is a novel siderophore cephalosporin, which has proven in vitro activity against carbapenem-resistant (CR) Gram-negative pathogens and stability towards all carbapenemases. The aim of this study was to describe the first cases of prescriptions and the efficacy of cefiderocol for compassionate use in the 2 months following its access in France. We performed a national retrospective study of all patients who received at least one dose of cefiderocol from 2 November 2018 to 5 November 2019. We collected clinical characteristics and outcome through a standard questionnaire. Bacterial isolates from 12 patients were centralized and analyzed in the French National Reference Center for Antimicrobial Resistance, and sequenced using Illumina technology. Finally, 13 patients from 7 French university hospitals were included in the study. The main type of infection treated by cefiderocol was respiratory tract infections (RTI, n = 10). The targeted bacteria were Pseudomonas aeruginosa (n = 12), including carbapenemase-producing P. aeruginosa (n = 9), Acinetobacter baumannii (n = 2), Klebsiella pneumoniae (n = 1), and Enterobacter hormaechei (n = 1). Overall, of the 12 patients whose samples were analyzed, 5 P. aeruginosa strains were not susceptible to cefiderocol (4 categorized as resistant and 1 as intermediate) according to Clinical and Laboratory Standards Institute (CLSI) breakpoints. If considering susceptible strains, the cure rate was 6/7, while being 0/5 among not-susceptible strains. This study underlines the necessity to test strains in adequate conditions.